SZSabina Zaborowska

Sabina Zaborowska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sabina Zaborowska has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Association Between LPR, Obstructive Sleep Apnea, and Asthma - A Narrative Review

    by Matylda BęDkowska-Kuśmierek, Anna Złotnik, Kinga Krzysztofik, Antoni Klamka, Paulina Kawalec, Kamil Bronikowski, Maksymilian Ryszkowski, Krystian Fornal, Natalia BęDkowska-Kuśmierek, Sabina Zaborowska

    Background: Laryngopharyngeal reflux (LPR), obstructive sleep apnea (OSA), and asthma are common disorders increasingly recognized as interconnected conditions sharing inflammatory and mechanical mechanisms. Their coexistence may worsen symptoms and reduce quality of life. Aim: To review current evidence regarding the association between LPR, OSA, and asthma, including shared pathophysiological mechanisms and clinical implications. Material and Methods: A narrative review of meta-analyses, observational studies, and clinical reports examining prevalence, pathophysiology, clinical presentation, and treatment strategies related to LPR, OSA, and asthma. Results: Studies demonstrate a significant overlap among these conditions. LPR is frequently observed in patients with OSA and asthma, while OSA prevalence is increased in asthmatic individuals. Proposed mechanisms include chronic inflammation, obesity, autonomic dysfunction, upper airway instability, and nocturnal hypoxia, creating a bidirectional cycle in which each disorder may aggravate the others. Continuous positive airway pressure (CPAP) therapy may improve reflux symptoms and asthma control, whereas proton pump inhibitor treatment for LPR often provides limited benefit. Conclusions: LPR, OSA, and asthma may represent an overlapping clinical triad rather than isolated diseases. Awareness of their coexistence may improve diagnosis and support multidisciplinary management. Further prospective studies are needed to clarify causal relationships and optimize treatment strategies.

  • Open Access

    Large Language Models in Medicine: Opportunities, Limitations, and Future Directions – A Scoping Review

    by Antoni Klamka, Paulina Kawalec, Kamil Bronikowski, Maksymilian Ryszkowski, Krystian Fornal, Natalia BęDkowska-Kuśmierek, Sabina Zaborowska, Paulina Pawlak, Olaf Wojcieszuk, Łukasz Starczewski

    Introduction. Large language models (LLMs) are increasingly used in healthcare and health-related fields, including clinical decision support, personalized medicine, digital health, and sports performance monitoring. However, concerns regarding reliability, transparency, and safety continue to limit their broader implementation. Materials and Methods. A scoping review of 24 PubMed-indexed studies published between 2023 and 2026 was conducted to assess current applications, benefits, limitations, and future directions of LLMs in healthcare. Results. LLMs are being applied in clinical decision support, diagnostics, biomedical research, personalized healthcare, and digital health solutions. They can enhance information retrieval, clinical reasoning, literature synthesis, health monitoring, and sports-related applications such as training support and performance optimization. Emerging trends include retrieval-augmented generation, multimodal systems, and specialized AI agents. Key challenges include hallucinations, limited explainability, privacy concerns, and insufficient clinical validation. Conclusions. LLMs have significant potential to improve healthcare, biomedical research, and health-oriented sports applications. Currently, they should serve as supportive tools rather than autonomous decision-makers. Further progress requires robust validation, regulatory oversight, and effective human–AI collaboration.

  • Open Access

    REVISITING THE SAFETY PROFILE OF TOPICAL CALCINEURIN INHIBITORS IN ATOPIC DERMATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS (2015–2026) IN THE CONTEXT OF PUBLIC HEALTH REGULATIONS

    by Anna Złotnik, Kinga Krzysztofik, Antoni Klamka, Paulina Kawalec, Kamil Bronikowski, Maksymilian Ryszkowski, Krystian Fornal, Natalia BęDkowska-Kuśmierek, Sabina Zaborowska, Paulina Pawlak

    Background. Atopic Dermatitis (AD) is a widespread, chronic inflammatory-related skin con-dition. Despite the effectiveness of topical calcineurin inhibitors (TCIs), their use is often limited by "TCI phobia" fueled by FDA "black box" warnings regarding potential oncological risks. These warnings were based on animal model studies conducted early in the development of the drug and systemic transplantation data. Aim. The aim of this study is to evaluate the oncological safety of TCIs in patients with atopic dermatitis by synthesizing the latest epidemiological evidence (2015–2026) and to discuss the implications of current public health regulator restrictions. Material and methods. A systematic review and meta-analysis adhered to the PRISMA 2020 guidelines. Databases (PubMed, Embase) were searched for cohort and case-control studies. Ten high-quality studies (Newcastle-Ottawa Scale ≥7) were selected. Statistical analysis was performed using JASP (Version 0.18.3) with a random-effects model (Restricted ML) to calcu-late pooled Relative Risks (RR) and evaluate heterogeneity (I2). Results. The quantitative synthesis included diverse age and geographical cohorts. The analysis revealed that TCI use is not associated with a statistically significant increase in the overall risk of malignancy (pooled RR = 0.97; 95% CI: 0.82–1.15; p = 0.529). Heterogeneity was non-existent (I2 = 0%). Long-term data (e.g., APPLES study) and large-scale pharmacovigilance reports (17 million FAERS records) confirmed no increased risk of lymphomas or hematopoietic malignancies. Conclusions. The oncological safety profile of TCIs is favorable and supported by pharmaco-kinetic evidence, that shows minor systemic absorption (< 1.0 ng/mL). Systemic cancer cases associated with TCI(s) are most likely historically attributed to protopathic bias. These findings strongly supports the removal of the "black box" warnings to reduce "TCI phobia" and improve therapeutic outcomes and quality of life for AD patients.

  • Open Access

    Fecal Calprotectin: Beyond a Biomarker of Intestinal Inflammation

    by Kamil Bronikowski, Maksymilian Ryszkowski, Krystian Fornal, Natalia BęDkowska-Kuśmierek, Sabina Zaborowska, Paulina Pawlak, Olaf Wojcieszuk, Łukasz Starczewski, Adrianna Babik, Kamila Kamińska

    Background.Fecal calprotectin (FC), a neutrophil-derived S100A8/S100A9 heterodimer, is a widely used non-invasive biomarker of intestinal inflammation, particularly in inflammatory bowel diseases (IBD). Emerging evidence suggests its broader role in gut barrier dysfunction and systemic inflammation. Aim.To evaluate the clinical relevance of fecal calprotectin, focusing on its diagnostic performance, limitations, and emerging applications beyond IBD. Material and methods.A narrative review of PubMed-indexed literature was conducted, including original studies and reviews addressing the biological role of calprotectin, its diagnostic accuracy, and its association with intestinal permeability, microbiota, and metabolic inflammation. Results.Fecal calprotectin demonstrates high sensitivity for detecting intestinal inflammation and is useful in differentiating IBD from functional disorders such as irritable bowel syndrome. Its levels correlate with disease activity and are valuable in monitoring treatment response and predicting relapse. However, its specificity is limited, as elevated levels may occur in infections, malignancies, and drug-related mucosal injury. Recent studies suggest associations between FC, gut microbiota alterations, and low-grade systemic inflammation. Conclusions.Fecal calprotectin is a valuable tool in the diagnosis and management of intestinal inflammation. Its expanding role in systemic conditions highlights the need for further research to improve standardization and clarify its clinical applications

  • Open Access

    Association Between Psoriasis and Hashimoto’s Thyroiditis - A Systematic Review

    by Kinga Anna Krzysztofik, Antoni Klamka, Paulina Kawalec, Kamil Bronikowski, Maksymilian Ryszkowski, Krystian Fornal, Natalia BęDkowska-Kuśmierek, Sabina Zaborowska, Paulina Pawlak, Olaf Wojcieszuk

    Background Psoriasis is a chronic immune-mediated inflammatory disease increasingly associated with other autoimmune disorders, including autoimmune thyroid diseases, particularly Hashimoto’s thyroiditis. In recent years, numerous studies have investigated the relationship between psoriasis and thyroid dysfunction; however, the available evidence remains partly inconsistent. Objective The aim of this study was to evaluate the association between psoriasis and autoimmune thyroid diseases based on available observational studies, systematic reviews, and meta-analyses. Methods A literature review was conducted using publications available in PubMed, PMC, Frontiers, and MDPI databases. Observational studies, systematic reviews, meta-analyses, and Mendelian randomization studies investigating the relationship between psoriasis and thyroid diseases were included. Data regarding the prevalence of AITD, thyroid autoantibodies, and thyroid dysfunction in patients with psoriasis were analyzed. Results Available evidence indicates that patients with psoriasis have an increased risk of autoimmune thyroid diseases. In the meta-analysis by Zhang et al., including 253,313 psoriasis patients and 1,376,533 controls, psoriasis was associated with a significantly increased risk of AITD (OR = 1.76; 95% CI: 1.35–2.28), particularly Hashimoto’s thyroiditis (OR = 1.88; 95% CI: 1.50–2.35). Observational studies also demonstrated higher levels of anti-TPO and anti-TG antibodies, more frequent thyroid dysfunction, and ultrasonographic changes suggestive of thyroid autoimmunity among psoriasis patients. Conclusions Psoriasis is associated with an increased prevalence of autoimmune thyroid diseases, especially Hashimoto’s thyroiditis. The observed relationship may result from shared immunological and genetic mechanisms. Further prospective and causal studies are required to better understand the nature of this association.

  • Open Access

    Leadership Styles in Sport: A Systematic Review

    by Krystian Fornal, Natalia BęDkowska-Kuśmierek, Sabina Zaborowska, Paulina Pawlak, Olaf Wojcieszuk, Łukasz Starczewski, Adrianna Babik, Kamila Kamińska, Matylda BęDkowska-Kuśmierek, Anna Złotnik

    Background: Leadership is a central determinant of performance, well-being, and organisational effectiveness in sport. Despite a growing body of empirical work, no comprehensive systematic review has synthesised findings across all sport-related leadership contexts, including coaching, physical education, and sport management.Objective: This systematic review aimed to identify, describe, and critically analyse the evidence base on leadership styles in sport published between 2010 and 2025.Methods: A systematic search was conducted in PubMed using a pre-specified Boolean search string in accordance with PRISMA 2020 guidelines [9]. A total of 105 records were retrieved. Following title, abstract, and full-text screening against pre-defined inclusion and exclusion criteria, 43 studies were included in the final synthesis.Results: Transformational leadership was the dominant paradigm, featuring in approximately 65% of included studies. Authentic and servant leadership emerged as important complementary constructs, particularly in relation to athlete well-being and shared leadership. Evidence on destructive leadership was sparse but highlighted significant negative consequences. Leadership research in sport management and governance contexts remained markedly underrepresented.Conclusions: The literature on leadership in sport is heavily skewed towards coach–athlete dyads and transformational leadership theory. Significant gaps remain in the study of leadership within sport organisations and federations, non-Western contexts, and emerging constructs such as paradoxical and ambidextrous leadership. Future research should adopt multi-level and longitudinal designs.

  • Open Access

    Physical activity as a non pharmacological intervention in Alzheimer’s disease: a narrative review

    by Sabina Zaborowska, Paulina Pawlak, Olaf Wojcieszuk, Łukasz Starczewski, Adrianna Babik, Kamila Kamińska, Matylda BęDkowska-Kuśmierek, Anna Złotnik, Kinga Krzysztofik, Antoni Klamka

    Background. Alzheimer’s disease (AD) is the leading cause of dementia, and disease‑modifying pharmacological options remain limited. Physical activity (PA) has emerged as a promising modifiable factor to mitigate cognitive decline and disease progression. Aim. To synthesize evidence from clinical and mechanistic studies on the effects of PA in AD, with emphasis on cognition, disease course, and key biological pathways. Material and methods. A targeted narrative search of PubMed and Scopus identified English‑language studies (2002–2025), prioritizing randomized controlled trials, systematic reviews, and meta‑analyses of exercise or PA interventions in individuals with AD, mild cognitive impairment, or preclinical AD; additional observational and mechanistic work was used to contextualize clinical findings. Evidence was synthesized qualitatively, without formal risk‑of‑bias assessment or quantitative meta‑analysis, focusing on cognition, neuropsychiatric symptoms, function, quality of life, and major mechanistic domains. Results. Most studies show that PA improves global cognition (especially executive function) and reduces neuropsychiatric symptoms, while memory effects are more limited. Resistance and multicomponent training yield greater cognitive benefits than aerobic exercise alone, likely via enhanced neurotrophic signaling, reduced Aβ/tau pathology, improved insulin sensitivity, attenuated neuroinflammation, and increased cerebral blood flow. Moderate‑intensity PA (≈150–180 min/week) appears optimal, slowing clinical progression most clearly in preclinical and mild AD, although effects on quality of life remain inconsistent. Conclusions. PA is a promising, safe, and accessible non‑pharmacological intervention, particularly in earlier AD stages, and should be considered a core component of strategies to reduce the burden of AD.

  • Open Access

    The role of Dupilumab in the treatment of Bullous Pemphigoid, Pemphigus and Hailey-Hailey Disease: A Narrative Review

    by Natalia BęDkowska-Kuśmierek, Sabina Zaborowska, Paulina Pawlak, Olaf Wojcieszuk, Łukasz Starczewski, Adrianna Babik, Kamila Kamińska, Anna Złotnik, Matylda BęDkowska-Kuśmierek, Kinga Krzysztofik

    Background: Autoimmune bullous diseases (AIBDs) and Hailey-Hailey disease are chronic skin disorders characterized by blister formation, pruritus, and reduced quality of life. Standard treatments, including systemic corticosteroids and immunosuppressants, often cause adverse effects and may not achieve long-term remission. Dupilumab, a monoclonal antibody targeting IL-4 and IL-13, has emerged as a promising alternative. Aim: To evaluate the efficacy and safety of dupilumab in patients with bullous pemphigoid, pemphigus vulgaris and foliaceus, and Hailey-Hailey disease. Material and Methods: Literature review including meta-analyses, randomized trials, retrospective studies, and case reports on dupilumab use in AIBDs and Hailey-Hailey disease. Disease activity was assessed using PDAI, BPDAI, or clinical evaluation; quality of life and adverse events were summarized. Results: In bullous pemphigoid, dupilumab reduced disease activity, pruritus, and cumulative corticosteroid dose, with most patients achieving complete or partial remission. Evidence in pemphigus vulgaris and foliaceus is limited but suggests potential benefit, particularly in patients ineligible for rituximab. In Hailey-Hailey disease, dupilumab improved lesions and quality of life, although relapse after discontinuation was reported. Therapy was generally well tolerated- with main adverse events being: injection site reactions, conjunctivitis, and eosinophilia. Conclusions: Dupilumab is an effective and safe option in bullous pemphigoid, offering pruritus relief and steroid-sparing benefits. Its use in pemphigus and Hailey-Hailey disease is promising but experimental. Further high-quality studies are needed to confirm long-term efficacy and safety.

  • Open Access

    Metformin as a Potential Geroprotective Agent: Mechanisms, Clinical Evidence and Implications for Healthy Aging

    by Paulina Kawalec, Kamil Bronikowski, Maksymilian Ryszkowski, Krystian Fornal, Natalia BęDkowska-Kuśmierek, Sabina Zaborowska, Paulina Pawlak, Olaf Wojcieszuk, Łukasz Starczewski, Adrianna Babik

    Background: Population aging represents a major medical and socioeconomic challenge worldwide. The increasing prevalence of age-related diseases, including cardiovascular disorders, neurodegeneration, cancer, and metabolic dysfunction, highlights the need for strategies aimed at extending healthspan rather than lifespan alone. In this context, pharmacological agents that modulate fundamental biological processes of aging have attracted significant attention. Metformin has emerged as a potential candidate beyond its established role in the treatment of type 2 diabetes mellitus. Aim: This narrative review aimed to evaluate current evidence regarding the potential geroprotective properties of metformin, with particular emphasis on underlying molecular mechanisms and available clinical data. Materials and Methods: A narrative literature review was conducted using the PubMed database. Articles published between January 2015 and March 2025 were identified using the keywords “metformin”, “aging”, “longevity”, and “geroprotection”. Peer-reviewed original studies and review articles in English were included, while case reports and non-peer-reviewed publications were excluded. Results: Evidence indicates that metformin influences multiple pathways involved in aging, including activation of AMP-activated protein kinase (AMPK), inhibition of the mechanistic target of rapamycin (mTOR), modulation of mitochondrial metabolism, reduction of oxidative stress, and attenuation of chronic inflammation. Observational studies suggest associations with reduced incidence of age-related diseases and improved survival; however, direct evidence in non-diabetic populations remains limited. Conclusions: Metformin demonstrates properties consistent with potential geroprotective effects. However, well-designed randomized controlled trials are required to confirm its efficacy and safety in the context of healthy aging.

  • Open Access

    Psoriasis, epidemiology, etiopathogenesis, clinical presentation, treatment – a systematic review

    by Maksymilian Ryszkowski, Krystian Fornal, Natalia BęDkowska-Kuśmierek, Sabina Zaborowska, Paulina Pawlak, Olaf Wojcieszuk, Łukasz Starczewski, Adrianna Babik, Kamila Kamińska, Matylda BęDkowska-Kuśmierek

    Introduction: Psoriasis is a chronic, relapsing, systemic inflammatory disease with an immunological basis and a strong genetic predisposition, affecting approximately 1–3% of the population. Its pathogenesis involves dysregulated immune responses with activation of T lymphocytes and overproduction of proinflammatory cytokines such as IL-17, IL-23, and TNF-α, leading to excessive keratinocyte proliferation. The disease has a multisystem character and is frequently associated with psoriatic arthritis, cardiovascular diseases, metabolic disorders, and depression. Aim: The aim of this study was to review current literature on the epidemiology, etiopathogenesis, clinical presentation, and contemporary treatment of psoriasis, with particular emphasis on its systemic nature and associated comorbidities. Conclusions: Psoriasis is a complex chronic disease requiring an individualized therapeutic approach. The severity and duration of skin lesions are associated with an increased risk of systemic complications, particularly cardiovascular and metabolic disorders. The development of biologic agents and small-molecule therapies has significantly improved treatment effectiveness and patients’ quality of life. Effective management should include both control of cutaneous symptoms and treatment of comorbid conditions. Keywords: psoriasis; epidemiology; etiopathogenesis; clinical presentation; treatment; comorbidities; biologic therapy; systemic inflammation.